

July 2009 Clinical Trials Update

By Jim Hughes
 LRG Clinical Trials Coordinator

In this month's Clinical Trials Bulletin we highlight a new class of drugs that target Insulin-like Growth Factor 1 Receptor (IGF-1R). IGF-1R is a tyrosine kinase that, much like KIT, protrudes through the cell surface and begins to signal when an extracellular Insulin Growth Factor (IGF1) attaches to the outside portion of the receptor. Unlike KIT, IGF-1R has not been found to be mutated in GIST. However, IGF-1R has been found to be over-expressed in wild-type GIST tumor tissue. Up to now, KIT inhibitors have had limited impact in wild type GIST. IGF-1R is now viewed as a component of a potential "side channel" providing an alternative signaling path to KIT and potentially a target in GIST.

In experiments with wildtype GIST cells, researchers at Fox Chase Cancer

Center have demonstrated the ability to slow cell growth with both IGF-1R inhibitors and combinations of IGF-1R and KIT inhibitors. These promising results are leading to new trial designs specifically for GIST patients.

IGF-1R inhibitors are a very active area of drug development. We have identified over a dozen compounds both in the lab and in early clinical trials. Many are in trials that are open to solid tumors or advanced malignancies and should accept GIST patients.

As with all Phase I trials, the trial objective is to determine a safe dosage and to document safety issues. Efficacy is not determined until phase II or III. Patients entering phase I are not guaranteed a therapeutic dosage nor is there an easy way of measuring all the risks. However, for those experiencing resistance or uncontrollable growth, Phase I trials provide an option until the new GIST-specific trials, such as the planned NIH

trial, are on-line.

IGF-1R inhibitors are of two types: small molecule and monoclonal-antibodies.

Small molecule inhibitors work in much the same way as Imatinib or Sunitinib work against KIT. They block the IGF-1R molecule usually at a signaling point inside the cell.

Monoclonal antibodies work by binding to the IGF-1R protein portion outside the cell and thereby prevent the IGF1 ligand from binding to the receptor and initiating the tyrosine kinase signaling process.

Both methods can effectively stop IGF-1R signaling. Monoclonal antibodies tend to be more specific to their targets.

See Page 2

The Life Raft Group

Who are we, what do we do?


The Life Raft Group (LRG) directs research to find a cure for a rare cancer and help those affected through support and advocacy until we do.

The LRG provides support, information and assistance to patients and families with Gastrointestinal Stromal Tumor (GIST). The LRG achieves this by providing an online community for patients and caregivers, supporting local in-person meetings, patient education through monthly newsletters and webcasts, one-on-one patient consultations, and most importantly, managing a major research project to find the cure for GIST.

Disclaimer

We are patients and caregivers, not doctors. Information shared is not a substitute for discussion with your doctor. For the very latest information, see the LRG Clinical Trials database at: http://liferaftgroup.org/treat_trials.html.

Insulin-like Growth Factor Receptor signaling



FROM PAGE 1

Small molecules can have collateral targets that can either enhance tumor inhibition and/or caused unwanted side-effects. Most IGF-1R inhibitors in trials today are monoclonal antibodies. The exceptions are OSI-906 and XL228.

When drugs are assigned a generic

name you can usually tell which are monoclonal antibodies because they all have the suffix 'mab'. Figitumumab (CP-751,871) and Cixutumumab (IMC-A12) are two examples.


One caution when evaluating IGF-1R trials is to be aware that some trials preclude the use of any prior IGF-1R therapy (BIIB022 and AMG 479). You may

want to take this into account in optimizing your trial plan.

In this months report we have included eleven new Phase 1 trials of IGF-1R inhibitors. Two of these will accept patients younger than eighteen. This months report also reflects the termination of the imatinib plus RAD001 trial that was accruing at nine sites in Germany.

Phase 1 Options for Advanced Wild Type GIST:

IGF-1R Inhibitors



Don't forget to check out the LRG Newsletter at www.gistnews.org!

*Exclude prior IGF-1R inhibitor therapy

Note: Trials are first grouped together by treatment phase. For example, the first grouping lists 2 trials that are open to patients in all treatment stages. Each trial description also lists the treatment stage under the "Stage" heading. Trials that are specifically for GIST are listed first. Trials are then sorted by phase in descending order) and then by drug name. Trial sites are sorted by country, state and then city.

**Treatment Stage:
All**

Imatinib

Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor

Phase: 2
 Stage: All
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: [NCT00764595](#)
 Contact: See site contact info below
Niigata University Medical and Dental School
 Niigata, Japan
 81-25-227-2228
 Tatsuo Kanda, MD

Surgery

Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor

Phase: 2
 Stage: All
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: Surgery
 Strategy: Surgery
 NCT #: [NCT00769782](#)
 Contact: See site contact info below
Niigata University Medical and Dental School
 Niigata, Japan
 81-25-227-2228
 Tatsuo Kanda, MD

**Treatment Stage:
First-line**

Imatinib + Bevacizumab

Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

Phase: 3
 Stage: First-line
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor+ VEGF inhibitor (antibody)
 Strategy: Block KIT
 Block tumor blood vessel growth
 NCT #: [NCT00324987](#)
 Contact: See each trial site.

USC/Norris Comprehensive Cancer Center
 Los Angeles, CA USA
 Clinical Trials Office
 323-865-0451

Iowa Oncology Research Association - CCOP
 Des Moines, IA USA
 515-244-7586
 Roscoe F. Morton, MD

University of Chicago
 Chicago, IL USA
 Clinical Trials Office, 773-834-7424
 Hedy Kindler, MD

Wichita - CCOP
 Wichita, KS USA
 316-262-4467
 Shaker R. Dakhil, MD

Michigan Cancer Research Consortium - CCOP
 Ann Arbor, MI USA
 734-434-4930
 Phillip J. Stella, MD

Kalamazoo - CCOP
 Kalamazoo, MI USA
 269-373-7458
 Raymond S. Lord, MD

Metro Minnesota - CCOP
 St. Louis Park, MN USA
 952-993-1517
 Patrick J. Flynn, MD

Ozarks Regional - CCOP
 Springfield, MO USA
 417-269-4520
 John W. Goodwin, MD

University of Mississippi Cancer Clinic
 Jackson, MS USA
 Robert D. Hamilton
 601-984-5590

Montana Cancer Consortium - CCOP
 Billings, MT USA
 406-238-6290
 Benjamin Marchello, MD

Southeast Cancer Control Consortium - CCOP
 Winston-Salem, NC USA
 910-777-3036
 James M. Atkins, MD

Roswell Park Cancer Institute
 Buffalo, NY USA
 Clinical Trials Office
 877-275-7724

Syracuse Hematology-Oncology Associate of Central New York - CCOP
 East Syracuse, NY USA
 315-472-7504
 Jeffrey J. Kirshner, MD

Columbus - CCOP
 Columbus, OH USA
 614-443-2267
 Philip J. Kuebler, MD

Dayton Clinical Oncology Program - CCOP
 Kettering, OH USA
 937-395-8678
 Howard M Gross, MD

Toledo Community Hospital Oncology - CCOP
 Toledo, OH USA
 419-255-5433
 Paul L. Schaefer, MD

Columbia River Oncology Program - CCOP
Portland, OR USA
503-216-6260
Janet C Ruzich

Knight Cancer Institute at Oregon Health Sciences University (OHSU)
Portland, OR USA
503 494-6594
Michael Heinrich, MD

Geisinger Clinical & Medical Center - CCOP
Danville, PA USA
570-271-6413
Albert M. Bernath, MD

Fox Chase Cancer Center
Philadelphia, PA USA
1-888-FOX-CHASE
Margeret von Mehren, M.D.

Gibbs Regional Cancer Center - CCOP
Spartanburg, SC USA
864-560-7050
James Bearden, III, MD

Cancer Therapy and Research Center
San Antonio, TX USA
Clinical Trials Office
210-616-5798

University of Texas Health Science Center
San Antonio, TX USA
Dorothy Nguyen
210-567-4777

Fred Hutchinson Cancer Research Center
Seattle, WA USA
206-386-2441
Saul E. Rivkin, MD

Marshfield Medical Research & Education Foundation - CCOP
Marshfield, WI USA
715-387-5426
Mohammad Q. Khan, MD, FACP

Masitinib, (AB1010)

Efficacy and Safety of Masitinib (AB1010) in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour

Phase: 3
Stage: First-line
Conditions: Gastrointestinal Stromal Tumor
Drug Type: KIT/PDGFR inhibitor
Strategy: Block KIT
NCT #: [NCT00812240](#)
Contact: Centre Oscar Lambret
Antoine Adenis, M.D.
a-adenis@o-lambret.fr
+33 (0)3 20 29 59 59
Hopital Jean Minjot
Besancon, France

Institut Bergonie
Bordeaux, France
Binh Bui Nguyen, MD

Centre Georges Francois Leclerc
Dijon, France

Centre Hospitalier Victor Jousselin
Dreux, France

Centre Oscar Lambret - Lille
Lille, France
Antoine Adenis, MD

Centre Leon Berard
Lyon, France
+33607507064
blay@lyon.fnclcc.fr
Jean Yves-Blay, MD, PhD

Institut Paoli Calmette
Marseilles, France
Patrice Viens, MD, PhD

Centre Val d'Aurele
Montpellier, France

Centre Rene Gauducheau
Nantes, France

Hopital de la Source
Orleans, France

Hopital Europeen Georges Pompidou
Paris, France

Hopital Robert Debre
Reims, France

Hopital Charles Nicolle
Rouen, France

Centre Rene Huguenin
Saint-Cloud, France

Hopital Saint-Georges
Beirut, Lebanon

American University Hospital
Beirut, Lebanon

Middle East Institute of Health
Bsalim, Lebanon

Hopital Saint-Joseph
Dora, Lebanon

Hamoud Hospital
Saïda, Lebanon

MD Anderson - Orlando
Orlando, FL USA
Clinical Trials Office - M.D.
Anderson Cancer Center,
713-792-3245
Jon Trent, MD, PhD

Henry Ford Health System
Detroit, MI USA

Beth Israel Medical Center
New York, NY USA

Nilotinib or Imatinib

*Phase III, Open-Label Study of
Nilotinib Versus Imatinib in GIST
Patients*

Phase: 3
Stage: First-line
Conditions: Gastrointestinal Stromal
Tumor
Drug Type: KIT/PDGFRA inhibitor
Strategy: Block KIT
NCT #: [NCT00785785](#)
Contact: Novartis Pharmaceuticals
+1-800-340-6843

**Universitätsklinik f. Innere
Medizin Onkologische
Ambulanz**
Innsbruck, Austria
Annaliese Gächter
+43 512 504 23333
annaliese.gaechter@uki.at
Eisterer Wolfgang, MD

**Universitätsklinik f. Innere
Medizin I**
Vienna, Austria
Thomas Brodowicz, MD
+43-40400-4466
+43-40400-4685
Thomas Brodowicz, MD

Hotel Dieu du Quebec
Quebec, Canada
Ann Wright
1-418-691-2950
Felix Couture, MD
1-418-691-5225
Felix Couture, MD

Mount Sinai Hospital
Toronto, ON Canada
Martin Blackstein, MD
011-416-586-5371
Martin Blackstein, MD

**Ottawa Regional Cancer
Center University of
Ottawa**
Ottawa, Ontario Canada
Tim Asmis, MD
613-737-7700 ext 70316
Tim Asmis, MD

**Maisonneuve-Rosemont
Hospital**
Montreal, QC Canada
Jacinthe Lasalle, MD
514-252-3400 ext 4670
Lucas Sideris, MD

**CHUM - Hopital Notre-
Dame**
Montreal, Quebec Canada
Chantal Gosselin
514-890-8000 ext. 24892
Denis Soulieres, MD

**CHUS - Hospital
Fleurimont**
Sherbrooke, Quebec Canada
Brigitte Jean
1-819-346-1110 ext. 12872
Rami Kotb, MD

**Aichi Cancer Center
Hospital**
Aichi, Japan
Akira Sawaki, MD
+81-52-762-6111
jutaku_a@aichi-cc.jp
Akira Sawaki, MD

**National Cancer Center
Hospital East**
Chiba, Japan
Toshihiko Doi, MD
+81-4-7133-1111
tdoi@east.ncc.go.jp
Toshihiko Doi, MD

**Hokkaido University
Hospital**
Hokkaido, Japan
Yoshito Komatsu
+81-11-706-5657
Yoshito Komatsu, MD

Kanagawa Cancer Center
Kanagawa, Japan
Haruhiko Cho, MD
+81-45-391-5791
Haruhiko Cho, MD

**Kumamoto University
Hospital**
Kumamoto, Japan
Hideo Baba, MD
+81-96-344-2111
hdobaba@kumamoto-u.ac.jp
Hido Baba, MD

**Niigata University Medical
and Dental School**
Niigata, Japan
Tatsuo Kanda, MD
+81-25-227-0372
kandat@med.niigata-u.ac.jp
Tatsuo Kanda, MD

**National Hospital
Organization - Osaka
General Hospital**
Osaka, Japan
Toshimasa Tsujinaka, MD
+81 6 6942 1331
toshi@onh.go.jp
Toshimasa Tsujinaka, MD

Osaka University Hospital
Osaka, Japan
Toshirou Nishida, MD
+81-6-6879-5111
toshin@surg1.med.osaka-u.
ac.jp
Toshirou Nishida, MD

Shizuoka Cancer Center
Shizuoka, Japan
Yusuke Onozawa
+81-55-989-5222
y.onozawa@scchr.jp
Yusuke Onozawa, MD

**National Cancer Center
Hospital**
Tokyo, Japan
Yasuhide Yamada, MD
+81 33 542 5111
yayamada@ncc.go.jp
Yasuhide Yamada, MD

**Consorci Hospitalari Parc
Tauli**
Barcelona, Spain
Jose G. Ruiz
+34-937-242-579
jgarciar@tauli.cat
Charles Pericay, MD

University Hospital La Paz
Madrid, Spain
Cristobal Belda-Iniesta, MD
34-1-2071138
cbelda.hulp@salud.madrid.
org
Cristobal Belda-Iniesta, MD

Chulalongkorn University
Bangkok, Thailand
Virote Sriuranpong, MD
+66-2-256-4533
vsmtcu40@gmail.com
Virote Sriuranpong, MD

Siriraj Hospital
Bangkok, Thailand
Vichien Srimuninnimit, MD
+66-2-419-4488
vsrimuninnimit@gmail.com

Vichien Srimuninnimit, MD

**Prince of Songkla
University**
Songkla, Thailand
Patrapim Sunpaweravong,
MD
+66-74-451-469
spatrapim@medicine.psu.ac.th
Patrapim Sunpaweravong,
MD

City of Hope
Duarte, CA USA
Neeti Arora
626-256-4673 xt 63019
narora@coh.org
Warren Chow, MD

City of Hope - Pasadena
Pasadena, CA USA
Doni Woo, RN
626-396-2900
Mark McNamara, MD

MD Anderson Cancer Center
Houston, TX USA
Diane Gravel
713-563-6702
dgravel@mdanderson.org
Vu Ta
713-792-2848
Jon Trent, MD, PhD

Dasatinib (BMS-354825)

Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors

Phase: 2
Stage: First-line
Conditions: Gastrointestinal Stromal Tumor
Drug Type: KIT/PDGFRA inhibitor + SRC inhibitor
Strategy: Block KIT + Block KIT Signal Path
NCT #: [NCT00568750](#)
Contact: See site contact info below

Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland
41-21-314-0150
Michael Montemurro, MD

Nilotinib

Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib. (OPEN)

Phase: 2
Stage: First-line
Conditions: Gastrointestinal Stromal Tumor
Drug Type: KIT/PDGFRA inhibitor
Strategy: Block KIT
NCT #: [NCT00756509](#)
Contact: Novartis Basel
+ 41 61 324 1111

Site name unknown, Bad Saarow
Bad Saarow, Germany

Site name unknown, Milan
Milan, Italy

**Treatment Stage:
Gleevec-resistant**

Sunitinib

Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant

Phase: 4
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal Tumor
Drug Type: KIT/PDGFRA inhibitor
Strategy: Block KIT
NCT #: [NCT00793871](#)
Contact: Pfizer Oncology Clinical Trial Information Service
1-877-369-9753
PfizerCancerTrials@emergingmed.com
Pfizer CT.gov Call Center
1-800-718-1021

Site name unknown Beijing 100035
Beijing, China

Site name unknown Beijing 100071
Beijing, China

Site name unknown, Beijing 100021
Beijing, China

Site name unknown, Nanjing 210002
Nanjing, Jiangsu China

Sunitinib or Imatinib

*Safety And Effectiveness Of Daily
Dosing With Sunitinib Or Imatinib In
Patients With Gastrointestinal
Stromal Tumors (Resistant at 400 mg*

Phase: 3
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal
Tumor
Drug Type: KIT/PDGFR inhibitor
Strategy: Block KIT
NCT #: [NCT00372567](#)
Contact: Pfizer Oncology Clinical
Trial Information Service
1-877-369-9753
PfizerCancerTrials@emerging
gmed.com
1-800-718-1021

**Site name unknown,
Marseille, France 13385**
Marseille, France

**Site name unknown,
Goettingen 37075**
Goettingen, Germany

**Site name unknown,
Hamburg 22767**
Hamburg, Germany

**Southwest German Cancer
Center at Eberhard-Karls
University**
Tuebingen, Germany
49-707-1298-2127
joerg.hartmann@med.uni-
tuebingen.de
Joerg T. Hartmann, MD

**Site name unknown, Hong
Kong, 0**
Hong Kong, Hong Kong

**Site name unknown, Lai
Chi Kok 0**
Lai Chi Kok, Kowloon Hong
Kong SAR

**Site name unknown, Tuen
Mun 0**
Tuen Mun, New Territories
Hong Kong SAR

**Site name unknown,
Bologna 40138**
Bologna, Italy

**Istituto Nazionale Dei
Tumori**
Milan, Italy
Paolo Casali MD

**Site name unknown, San
Giovanni Rotondo 71013**
San Giovanni Rotondo,
Foggia Italy

**Site name unknown, Seoul
135-710**
Seoul, Republic of Korea

**Site name unknown, Seoul
138-736**
Seoul, Republic of Korea

**Site name unknown, Seoul
110-744**
Seoul, Republic of Korea

**Site name unknown,
Barcelona 08036**
Barcelona, Spain

**Site name unknown,
Valencia 46009**
Valencia, Spain

**Site name unknown,
Glasgow G12 0YH**
Glasgow, UK

Royal Marsden Hospital
London, UK

**Site name unknown,
London NW1 2PG**
London, UK

**Site name unknown,
London W1**
London, UK

**Christie Hospital NHS
Trust**
Manchester, Lancashire UK

Karmanos Cancer Institute
Detroit, MI USA
all (800) KARMANOS (1
-800-527-6266) or e-mail
info@karmanos.org.
Anthony Shields, MD

**Site name unknown,
Farmington Hills 48334**
Farmington Hills, MI USA

**Site name unknown,
Henderson 89074**
Henderson, NV USA

**Site name unknown, Las
Vegas 89102**
Las Vegas, NV USA

**Site name unknown, Las
Vegas 89106**
Las Vegas, NV USA

**Site name unknown, Las
Vegas 89148**
Las Vegas, NV USA

**Cleveland Clinic Taussig
Cancer Center**
Cleveland, OH USA

Fox Chase Cancer Center
Philadelphia, PA USA
1-888-FOX-CHASE
Margaret von Mehren, M.D.

BIIB021 (CNF2024)

*An Open-Label, 18FDG-PET
Pharmacodynamic Assessment of the
Effect of BIIB021 in Subjects With
Gastrointestinal Stromal Tumors*

Phase: 2
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal
Tumor
Drug Type: HSP90 inhibitor
Strategy: Destroy KIT
NCT #: [NCT00618319](#)
Contact: Biogen Idec
oncologyclinicaltrials@bioge
nidec.com

**Site name unknown,
Rochester**
Rochester, MN USA

**Memorial Sloan-Kettering
Cancer Center**
New York, NY USA
Robert Maki, MD

Nilotinib

Nilotinib in Advanced GIST

Phase: 2
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal Tumor
Drug Type: KIT/PDGFR inhibitor
Strategy: Block KIT
NCT #: [NCT00782834](#)
Contact: See site contact info below
Fox Chase Cancer Center
Philadelphia, PA USA
1-888-FOX-CHASE (369-2427)
Margeret von Mehren, M.D.

Nilotinib

Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or

Phase: 2
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal Tumor
Drug Type: KIT/PDGFR inhibitor
Strategy: Block KIT
NCT #: [NCT00633295](#)
Contact: Novartis Basel
41 61 324 1111
Site name unknown, Tel Aviv
Tel Aviv, Israel
Site name unknown, Tel Hashomer
Tel Hashomer, Israel

Sorafenib (Nexavar, BAY 43-9006)

Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With

Phase: 2
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal Tumor
Drug Type: KIT/PDGFR inhibitor+ VEGF inhibitor (TKI) + RAF inhibitor
Strategy: Block KIT + Block KIT Signal Path
NCT #: [NCT00265798](#)
Contact: Clinical Trials Office - University of Chicago Cancer Research
773-834-7424
University of Chicago
Chicago, IL USA
Clinical Trials Office, 773-834-7424
Hedy Kindler, MD

Imatinib + Sunitinib

Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors

Phase: 1
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal Tumor
Drug Type: KIT/PDGFR inhibitor
Strategy: Block KIT
NCT #: [NCT00573404](#)
Contact:
Vanderbilt-Ingram Cancer Center-Cool Springs
Franklin, TN USA
615 343-4128
Jordan Berlin
Vanderbilt-Ingram Cancer Center at Franklin
Franklin, TN USA
615 343-4128
Jordan Berlin

Vanderbilt-Ingram Cancer Center
Nashville, TN USA
800 811-8480
Clinical Trials Office

Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors

Phase: 4
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal Tumor
Drug Type: VEGFR inhibitor (TKI)
Strategy: Block tumor blood vessel growth
NCT #: [NCT00777504](#)
Contact: See site contact info below
University Medical Center Nijmegen st Raboud
Nijmegen, Gelderland
Netherlands
31 24 3610353
c.vanherpen@onco.umcn.nl

C.M.L. van Herpen, Md, PhD

Dasatinib (BMS-354825)

Trial of Dasatinib in Advanced Sarcomas

Phase: 2
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal Tumor
Drug Type: KIT/PDGFR inhibitor + SRC inhibitor
Strategy: Block KIT + Block KIT Signal Path
NCT #: [NCT00464620](#)
Contact: Kathleen Granlund
kegranlund@sarctrials.org
734-930-7607

Arkansas Children's Hospital
Little Rock, AR USA
Bryce Warren
WarrenBryceA@uams.edu
Kimo Stine

City of Hope
Duarte, CA USA
Neeti Arora
626-256-4673 ext. 63019
NArora@coh.org
Warren Chow, MD

**Cedars-Sinai Outpatient
Cancer Center**

Los Angeles, CA USA
Chi Vu
310-423-2133
CVu@csocc.com
Charles Forscher, MD

Stanford Cancer Center

Palo Alto, CA USA
Maria Ahem
650-725-6413
mahem@stanford.edu

Kristen Ganjoo, MD

Sarcoma Oncology Center

Santa Monica, CA USA
Viky Chua
(310) 552-9999
vikychua@aol.com
Sant Chawla, MD

**Washington Cancer
Institute**

Washington, DC USA
Christina Sheeran,
202 877-5371
christina.m.
sheeran@medstar.net
Dennis A. Priebat, MD

**University of Iowa
Hospitals and Clinics**

Iowa City, IA USA
Melanie Frees, RN
319-356-1228
melanie-frees@uiowa.edu
Mohammed Milhem, MD

Kootenai Cancer Center

Coeur d'Alene, ID USA
Sheryl Goldon
208-666-2093
sgolden@kmc.org
Brian Samuels, MD

**Oncology Specialists, Park
Ridge**

Park Ridge, IL USA
Kathy Tolzien
847-268-8569
ktolzien@oncmed.net
Pamela Kaiser, MD

**Indiana University Simon
Cancer Center**

Indianapolis, IN USA
Kristen Potter, MS
317-278-6616
krpotter@iupui.edu
Daniel Rushing, MD

**Massachusetts General
Hospital**

Boston, MA USA
Anthony Thomas
617-643-5411
athomas2@partners.org
Edwin Choy, MD

**Dana Farber Cancer
Institute**

Boston, MA USA
Sarah Solomon
617-582-7503
ssolomon1@partners.org
James Butrynski, MD

**Johns Hopkins Sidney
Kimmel Comp Cancer
Center**

Baltimore, MD USA
Adult Oncology, 410-955
-8804
Pediatric Oncology, 410-955
-8751
David Loeb, MD, PhD

University of Michigan

Ann Arbor, MI USA
Gino Metko
734-647-2095
ginom@med.umich.edu
Scott Schuetze, MD, PhD

**Nebraska Methodist
Hospital**

Omaha, NB USA
Gladys Pierce
402-354-5129
gladys.peirce@nmhs.org
Kirsten Leu, MD

**Pennsylvania Oncology
Hematology Associates**

Philadelphia, PA USA
Deb Riordan, RN, BS
215-829-6712
debbieriordan@penncolog
y.com
Arthur Staddon, MD

Fox Chase Cancer Center

Philadelphia, PA USA
1-888-FOX-CHASE
Margeret von Mehren, M.D.

**University of Pittsburgh
Cancer Institute**

Pittsburgh, PA USA
Lynne Frydrych
412-623-4036
frydrychlm2@upmc.edu
Hussein Tawbi, MD, MSc

**MD Anderson Cancer
Center**

Houston, TX USA
Joanne Gigstad
713-563-0510
jgigstad@mdanderson.org
Shreyas Patel, MD

Everolimus

Treatment of Patients With RAD001

Who Have Progressive Sarcoma

Phase: 2
Stage: Gleevec-resistant
Conditions: Sarcoma
Drug Type: mTOR inhibitor
Strategy: Block KIT Signal Path
NCT #: [NCT00767819](#)
Contact: Novartis Pharmaceuticals
+1 800-340-6843

Site name unknown, Berlin
Berlin, Germany

**Site name unknown,
Dusseldorf**
Dusseldorf, Germany

**Site name unknown,
Mannheim 68135**
Mannheim, Germany

**Site name unknown,
Munchen**
Munchen, Germany

Site name unknown, Milan
Milan, Italy

Doxorubicin + Flavopiridol

*Doxorubicin and Flavopiridol in
Treating Patients With Metastatic or
Recurrent Sarcoma That Cannot Be
Removed By Surgery*

Phase: 1
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal
Tumor
Sarcoma
Drug Type: Transcription inhibitor +
Chemotherapy
Strategy: Freeze the cell division cycle
NCT #: [NCT00098579](#)
Contact: See site contact info below
**Memorial Sloan-Kettering
Cancer Center**
New York, NY USA
212-639-7573
dadamod@mskcc.org
David D'Adamo, MD, PhD,

Imatinib + IL-2

Imatinib + IL-2

Phase: 1
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal
Tumor
Drug Type: KIT inhibitor + Immune
stimulate
Strategy: Block KIT + Stimulate the
immune system
NCT #:
Contact: See site contact info below
Institut Gustave-Roussy
Villejuif Cedex, France
Patricia Pautier, MD
33 (0) 1 42 11 42 11
pautier@igr.fr
Laurence Zitvogel, MD

Multi-bacteria vaccine (MBV)

*A Phase I Study of Mixed Bacteria
Vaccine (MBV) in Patients With
Tumors Expressing NY-ESO-1
Antigen.*

Phase: 1
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal
Tumor
Drug Type: Immune stimulate
Strategy: Stimulate the immune system
NCT #: [NCT00623831](#)
Contact: See site contact info below
Krankenhaus Nordwest
Frankfurt, Germany
Antje Neumann
neumann.antje@khnw.de
069 7601 4161
Elke Jaeger, MD

SF1126

*A Phase I Open Label, Safety,
Pharmacokinetic and
Pharmacodynamic Dose Escalation
Study in SF1126, a PI Kinase (PI3K)*

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: PI3K inhibitor
Strategy: Block KIT Signal Path
NCT #: [NCT00907205](#)
Contact: See site contact info below
**TGen Clinical Research
Services**
Scottsdale, AZ USA
Cathy Costanza, RN, BS,
OCN
480-323-1550
ccostanza@shc.org
Jennifer Privratsky
480-323-1591
jprivratsky@shc.org
Ramesh Ramanathan, MD

Arizona Cancer Center
Tucson, AZ USA
Diane Rensvold, RN
520-694-9055
drensvold@azcc.arizona.edu
Judy Safarewitz, RN
520-694-9058
jsafarewitz@azcc.arizona.
edu
Daruka Mahadevan, MD,
PhD

Emory Winship Cancer Institute

Atlanta, GA USA
Almelida Rene
Merrieweather
404-778-1802
amerrie@emory.edu
Donald Harvey, PhD
404-778-4381
donald.
harvey@emoryhealthcare.
org

Indiana University Simon Cancer Center

Indianapolis, IN USA
Mary Jane Waddell, RN,
CCRC
317-274-7119
mjwaddell@iupui.edu
Jennifer M Funke, MS
317-278-0328
jmfunke@iupui.ed
E. Gabriela Chiorean, MD

AUY922

*Phase I-II Study to Determine the
Maximum Tolerated Dose (MTD) of
AUY922 in Advanced Solid
Malignancies, and Efficacy in HER2*

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: HSP90 inhibitor
Strategy: Destroy KIT
NCT #: [NCT00526045](#)
Contact: Novartis Pharmaceuticals
1 800 340-6843

**Site Name unknown,
Bellinzona**
Bellinzona, Switzerland

**David Geffen School of
Medicine at UCLA**
Los Angeles, CA USA
CBritten@mednet.ucla.edu
310-825-5268
Carolyn Britten, M.D.

Medical College of Georgia
Augusta, GA USA
706-721-2505
tsamuel@mcg.edu
Thomas Samuel, M.D.

Dana Farber Cancer Institute
Boston, MA USA
617 632-5053
stephen_hodi@dfci.harvard.edu
Stephen Hodi, MD, PhD

Washington University School of Medicine
St. Louis, MO USA
800-600-3606
info@ccadmin.wustl.edu
Timothy Pluard, MD

Nevada Cancer Institute
Las Vegas, NV USA
Sandy Lahr
(702) 822-5174
Nicholas Vogelzang, MD

MD Anderson Cancer Center
Houston, TX USA
800-392-1611 (in U.S.A.)
713-792-6161 (outside U.S.A.)
Jon Trent, MD, PhD

Cancer Therapy and Research Center
San Antonio, TX USA
210-562-1797
mmita@idd.org
Monica Mita, M.D.

BGT226

A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: mTOR inhibitor
PI3K inhibitor
Strategy: Block KIT Signal Path
NCT #: [NCT00600275](#)
Contact: Novartis
800 340-6843

Princess Margaret Hospital
Toronto, ON Canada
Lillian Siu, M.D.

Hospital Vall d'Hebron
Barcelona, Spain

Dana Farber Cancer Institute
Boston, MA USA
Melissa Hohos
617 632-2201
mhohos@partners.org
George Demetri, MD, PhD

Massachusetts General Hospital
Boston, MA USA
617-726-6225
nisaac1@partners.org
Stephen Isakoff, MD

Nevada Cancer Institute
Las Vegas, NV USA
Dianna Tercan
(702) 822-5483
Lin-Chi Chen, M.D., Ph.D.

Cancer Therapy and Research Center
San Antonio, TX USA
Epp Goodwin
210-450-5798
Francis Giles, MD

MP470

Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470,

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: KIT/PDGFR inhibitor
Strategy: Block KIT
NCT #: [NCT00894894](#)
Contact: SuperGen

Gil Fine, PhD
925-560-0100
gfine@supergen.com
Angelique Mittan, CLS
925-560-0100

TGen Clinical Research Services
Scottsdale, AZ USA
Raoul Tibes, MD

South Texas Accelerated Research Therapeutics (START)
San Antonio, TX USA
Jim Agnew, RN
Anthony Tolcher, MD

SNX-5422

SNX-5422 in Treating Patients With Solid Tumor or Lymphoma That Has Not Responded to Treatment

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: HSP90 inhibitor
Strategy: Destroy KIT
NCT #: [NCT00644072](#)
Contact:

Warren Grant Magnuson Clinical Center
Bethesda, MD USA
Clinical Trials Office
888-NCI-1937
Giuseppe Giaccone, MD, PhD

Vorinostat + Bortezomib

Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: HDAC inhibitor +
Proteasome inhibitor
Strategy: Inhibit protein translation +
Unblock cell death genes
NCT #: [NCT00227513](#)
Contact:

Carbone Cancer Center, University of Wisconsin
Madison, WI USA
Clinical Trials Office
608-262-5223
George Wilding, MD

AMG 479 + AMG 655

AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors

Phase: 2
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: IGF1R inhibitor + TNF Inhibitor
Strategy: Block related tumor signal paths
NCT #: [NCT00819169](#)
Contact: Amgen Call Center
866-572-6436

Site name unknown, Barcelona 08036
Barcelona, Spain

Site name unknown, Santa Monica 90403
Santa Monica, CA USA

University of Chicago
Chicago, IL USA
Clinical Trials Office, 773
-834-7424
Hedy Kindler, MD

Site name unknown, Indianapolis
Indianapolis, IN USA

Site name unknown, Detroit
Detroit, MI USA

AT13387

Phase I Study of HSP90 inhibitor AT13387 in solid tumors

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: HSP90 inhibitor
Strategy: Destroy KIT
NCT #: [NCT00878423](#)
Contact: Andrew Wolanski
617-632-6623
Andrew_Wolanski@dfci.harvard.edu

Beth Israel Deaconess Medical Center
Boston, MA USA
Sue Gotthardt RN, OCN
(617) 632-9272
Bruce Dezube M.D.

Massachusetts General Hospital
Boston, MA USA
Eunice Kwak, MD

Dana Farber Cancer Institute
Boston, MA USA
Geoffrey Shapiro, MD, PhD

BAY 73-4506

Phase I study of BAY 73-4506

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: KIT/PDGFR inhibitor
VEGFR inhibitor (TKI)
Strategy: Block KIT
NCT #:
Contact: See site contact info below

MD Anderson Cancer Center
Houston, TX USA
Clinical Trials Office
713-792-3245
Jon Trent, MD, PhD

South Texas Accelerated Research Therapeutics (START)
San Antonio, TX USA
Tracy Dufresne, RN
210-593-5265
tracy.dufresne@start.stoh.com

BEZ235

A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: mTOR inhibitor
PI3K inhibitor
Strategy: Block KIT Signal Path
NCT #: [NCT00620594](#)
Contact: Novartis
862-778-8300

Nevada Cancer Institute
Las Vegas, NV USA
Dianna Tercan
(702) 822-5483
Wolfram Samlowski, M.D.

Sarah Cannon Research Institute
Nashville, TN USA
615-329-7274
hburriss@tnonc.com
Howard A. Burris, III MD

BIIB021 (CNF2024)

Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: HSP90 inhibitor
Strategy: Destroy KIT
NCT #: [NCT00618735](#)
Contact: Biogen Idec
oncologyclinicaltrials@biogenidec.com

Premier Oncology, Santa Monica
Santa Monica, CA USA

South Texas Accelerated Research Therapeutics (START)
San Antonio, TX USA

BIIB022

Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: IGF1R inhibitor
Strategy: Block related tumor signal paths
NCT #: [NCT00555724](#)
Contact: Biogen Idec
oncologyclinicaltrials@biogenidec.com

Site name unknown, Los Angeles, CA
Los Angeles, CA USA

University of Colorado
Aurora, CO USA
Sarah Eppers
720-848-0052
SARAH.EPPERS@ucdenver.edu
Stephen Leong

Fox Chase Cancer Center
Philadelphia, PA USA
Kathleen Lear, RN, OCN,
CCRP Phone: 215-214-1511
Email: kathleen.lear@fccc.edu
Roger Cohen, MD

BKM120

A Phase IA, Multi-Center, Open-Label, Dose- Escalation Study of BKM120, Administered Orally on a Continuous Daily Dosing Schedule

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: PI3K inhibitor
Strategy: Block KIT Signal Path
NCT #:
Contact: See site contact info below

Sarah Cannon Research Institute
Nashville, TN USA
615-329-SCRI (7274)

BMS-754807

Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: IGF1R inhibitor
Strategy: Block related tumor signal paths
NCT #: [NCT00569036](#)
Contact: For site information outside the USA please email:
Clinical.

Trials@bms.com
First line of email MUST contain NCT# & Site#.

Site name unknown, East Melbourne
East Melbourne, Australia
Site # 003

Site name unknown, Footscray, Australia
Footscray, Victoria Australia
Site # 004

Site name unknown, Heidelberg Australia
Heidelberg, Victoria Australia
Site # 002

Site name unknown, Parkville, Australia
Parkville, Victoria Australia
Site #001

Cixutumumab + Temozolomide

Cixutumumab and Temozolomide in Treating Young Patients With Solid Tumors That Have Recurred or Not Responded to Treatment

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: IGF1R inhibitor + mTOR Inhibitor
Strategy: Block related tumor signal paths
NCT #: [NCT00880282](#)
Contact:

Children's Hospital of Orange County
Orange, CA USA
Violet Shen
714-532-8636

Children's National Medical Center
Washington, DC USA
Clinical Trials Office
202-884-2549

Masonic Cancer Center at University of Minnesota
Minneapolis, MN USA
Clinical Trials Office
612-624-2620

Cincinnati Children's Hospital Medical Center
Cincinnati, OH USA
Clinical Trials Office
513-636-2799

GDC-0941

A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: PI3K inhibitor
Strategy: Block KIT Signal Path
NCT #: [NCT00876109](#)
Contact: See site contact info below

TGen Clinical Research Services

Scottsdale, AZ USA
Lynne Hull
480-323-1071
LHull@SHC.org
Daniel D. Hoff, MD

Dana Farber Cancer Institute

Boston, MA USA
Melissa Hohos
617 632-2201
mhohos@partners.org
George Demetri, MD, PhD

Karmanos Cancer Institute

Detroit, MI USA
Jie Zhang
313-576-9365
zhangj@karmanos.org

GDC-0941

A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: PI3K inhibitor
Strategy: Block KIT Signal Path
NCT #: [NCT00876122](#)
Contact: See site contact info below

Royal Marsden Hospital

London, UK
Krunal Shah
0208 722 4005
Krunal.Shah@icr.ac.uk

IMC-A12 + CCI-779

IMC-A12 in Combination With Temsirolimus (CCI-779) in Patients With Advanced Cancers

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: IGF1R inhibitor + mTOR Inhibitor
Strategy: Block related tumor signal paths
NCT #: [NCT00678769](#)
Contact: Aung Naing, MD
713-563-0181

Karmanos Cancer Institute

Detroit, MI USA
all (800) KARMANOS (1
-800-527-6266) or e-mail
info@karmanos.org.

MD Anderson Cancer Center

Houston, TX USA
713-563-0181
Aung Naing, MD

IMC-A12 + CCI-779

Monoclonal Antibody IMC-A12 and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: IGF1R inhibitor + mTOR Inhibitor
Strategy: Block related tumor signal paths
NCT #: [NCT00678223](#)
Contact:

MD Anderson Cancer Center

Houston, TX USA
Clinical Trials Office - M.D.
Anderson Cancer Center,
713-792-3245
Aung Naing, MD

IPI-493

A Phase I Dose Escation Study of IPI-493

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: HSP90 inhibitor
Strategy: Destroy KIT
NCT #: [NCT00724425](#)
Contact: See site contact info below

Premier Oncology, Scottsdale

Scottsdale, AZ USA
Patricia Shannon, RN
480 860-5000 xt 223
pshannon@premiereoncology.com
David Mendelson, M.D.

San Diego Pacific Oncology and Hematology Associates

Encinitas, CA USA
Karen Brady, RN MSN
760-752-3340
kbrady@premiereoncology.com
Richard Just, M.D.

Premier Oncology, Santa Monica

Santa Monica, CA USA
Marilyn Mulay, NP
310-633-8400
mmulay@premiereoncology.com
Lee Rosen M.D.

University of Colorado

Aurora, CO USA
Stacy Grolnic, RN
720-848-0655
stacy.grolnic@uchsc.edu
Colin Weekes, MD, PhD

Mary Crowley Medical Research Center (Central Office)

Dallas, TX USA
Kay Easterwood-Sanchez
214-658-1943
Neil Senzer, MD

KW2450

Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: IGF1R inhibitor
Strategy: Block related tumor signal paths
NCT #: [NCT00921336](#)
Contact: Danyel Davis
(609) 919-1100
ddavis@kyowa-kirin-pharma.com
Niranjan Rao
(609) 919-1100
nrao@kyowa-kirin-pharma.com
Memorial Sloan-Kettering Cancer Center
New York, NY USA

MEDI-573

A Dose-Escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: IGF1R inhibitor
Strategy: Block related tumor signal paths
NCT #: [NCT00816361](#)
Contact: Jill Schmidt
301-398-0000
schmidtj@medimmune.com
Lorena DeRienzo
301-398-0000
de-rienzol@medimmune.com
Mayo Clinic, Jacksonville
Jacksonville, FL USA
Michele Maharaj
904-953-6136
maharaj.michele@mayo.edu
Michael E. Menefee, MD

Karmanos Cancer Institute
Detroit, MI USA
Karen Forman
313-576-8096
formank@karmanos.org
Pat LoRusso, DO

Mayo Clinic, Rochester
Rochester, MN USA
Janet Lensing
507-284-3137
lensing.janet@mayo.edu
Paul Haluska, MD, PhD

OSI-906

Phase I Study of Continuous OSI-906 Dosing

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: IGF1R inhibitor
Strategy: Block related tumor signal paths
NCT #: [NCT00514007](#)
Contact: OSIP Medical Information
800.572.1932, x7821
medical-information@osip.com

Beatson West of Scotland Cancer Centre
Glasgow, UK

Vanderbilt-Ingram Cancer Center
Nashville, TN USA

OSI-906

Phase I Study of Intermittent OSI-906 Dosing

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: IGF1R inhibitor
Strategy: Block related tumor signal paths
NCT #: [NCT00514306](#)
Contact: OSIP Medical Information
800.572.1932 ext 7821
medical-information@osip.com
Department of Cancer Therapeutics, Institute of Cancer Research
Sutton, Surrey UK
MD Anderson Cancer Center
Houston, TX USA
Edward Kim, MD

PX-478

Phase I Trial of PX-478

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: HIF-1 α inhibitor
Strategy: Block related tumor signal paths
Block tumor blood vessel
NCT #: [NCT00522652](#)
Contact: See site contact info below
TGen Clinical Research Services
Scottsdale, AZ USA
Lynne Hull
480-323-1071
lhull@shc.org
Daniel D. VonHoff, MD
MD Anderson Cancer Center
Houston, TX USA
Hala Abdulkadir
713-792-9944
habdulka@mdanderson.org
Roy S. Herbst, PhD

PX-866

Phase I Trial of Oral PX-866

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: PI3K inhibitor
Strategy: Block KIT Signal Path
NCT #: **NCT00726583**
Contact: See site contact info below

University of Colorado
Aurora, CO USA
Sharon hecker
720-848-0667
sharon.hecker@ucdenver.edu

Antonio Jimeno, MD

MD Anderson Cancer Center
Houston, TX USA
Rhonda Clement
713-563-3559
rclement@mdanderson.org
Roy Herbst, MD

R1507

A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: IGF1R inhibitor
Strategy: Block related tumor signal paths

NCT #: **NCT00560144**

Contact: Hoffmann-La Roche
Please reference Study ID Number: NO21200
973-235-5000
800-526-6367 (US only)

Site name unknown, Denver 80218
Denver, CO USA

Site name unknown, Bethesda 20982
Bethesda, MD USA

Memorial Sloan-Kettering Cancer Center
New York, NY USA
212-639-8267
Dr. Tanya Trippett

University of Pennsylvania
Philadelphia, PA USA

MD Anderson Cancer Center
Houston, TX USA
800-392-1611 Patients
800-392-1611 Referring MD
Cynthia E. Herzog

SNX-5422

Safety and Pharmacology of SNX-5422 Mesylate in Subjects With Refractory Solid Tumor Malignancies

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: HSP90 inhibitor
Strategy: Destroy KIT
NCT #: **NCT00506805**
Contact: Pfizer Oncology Clinical Trial Information
1-877-369-9753
PfizerCancerTrials@emergin.com
Pfizer CT.gov Call Center
1-800-718-1021

TGen Clinical Research Services
Scottsdale, AZ USA
Joyce Ingold RN
480-323-1339
jgold@shc.org
Daniel D. Von Hoff, MD

Sarah Cannon Research Institute
Nashville, TN USA
Jessica Gilbert
615 329-7238
Howard A. Burris, III MD

SNX-5422

Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: HSP90 inhibitor
Strategy: Destroy KIT
NCT #: **NCT00647764**
Contact: Pfizer Oncology Clinical Trial Information Service
1-877-369-9753
PfizerCancerTrials@emergin.com
Pfizer CT.gov Call Center
1-800-718-1021

Site name unknown, Bethesda 20982
Bethesda, MD USA

Sorafenib + Vorinostat

Phase I Vorinostat + Sorafenib in Patients With Advanced Solid Tumors

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: HDAC inhibitor + KIT/PDGFR inhibitor
Strategy: Block KIT + Unblock cell death genes + Destroy KIT
NCT #: **NCT00635791**
Contact: See site contact info below

University of Colorado
Aurora, CO USA
Stacy Grolnic
720-848-0655
stacy.grolnic@uchsc.edu
David Ross Camidge MD

STA-9090

*Study of STA-9090, Administered
Once-Weekly in Patients With Solid
Tumors*

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: HSP90 inhibitor
Strategy: Destroy KIT
NCT #: [NCT00687934](#)
Contact: See site contact info below

**Premier Oncology, Santa
Monica**

Santa Monica, CA USA
310-633-8400
Lee Rosen, MD

**US Oncology - Dayton
Oncology & Hematology**

Kettering, OH USA
robert.raju@usoncology.com
(937)293-1622
Robert Raju, MD

STA-9090

*Study of STA-9090, Administered
Twice-Weekly in Patients With Solid
Tumors*

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: HSP90 inhibitor
Strategy: Destroy KIT
NCT #: [NCT00688116](#)
Contact: See site contact info below

**Dana Farber Cancer
Institute**

Boston, MA USA
Melissa Hohos, RN,
617-632-2201
Geoffrey Shapiro, MD, PhD

**Massachusetts General
Hospital**

Boston, MA USA
Pilar De La Roche Mur
617-632-5841

**Beth Israel Deaconess
Medical Center**

Boston, MA USA
Pilar De La Roche Mur
617-632-5841

Karmanos Cancer Institute
Detroit, MI USA
Dr. Patricia LoRusso
313-576-8716

Sunitinib + CP-751,871

*Phase 1 Study of CP-751,871 in
Combination With Sunitinib in
Patients With Advanced Solid
Tumors*

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: KIT/PDGFR inhibitor +
IGF1R inhibitor
Strategy: Block KIT + Block related
tumor signal paths

NCT #: [NCT00729833](#)

Contact: EmergingMed
(877) 369-9753
PfizerCancerTrials@emergin
gmed.com
Pfizer CT.gov Call Center
1-800-718-1021

**Premier Oncology, Santa
Monica**

Santa Monica, CA USA
310 633-8400
Lee Rosen

**South Texas Accelerated
Research Therapeutics
(START)**

San Antonio, TX USA

XL147

*Study of the Safety and
Pharmacokinetics of XL147 in Adults
With Solid Tumors*

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: PI3K inhibitor
Strategy: Block KIT Signal Path
NCT #: [NCT00486135](#)
Contact: Exelixis Contact Line
866-939-4041

Hospital Vall d'Hebron

Barcelona, Spain
Gemma Sala
+34 93 489 4158
gsala@vhebron.net
Jose Baselga, MD, PhD

**Dana Farber Cancer
Institute**

Boston, MA USA
Pilar de la Rocha Mur
617-632-5841
pilar_DeLaRochaMur@dfci.
harvard.edu
Geoffrey Shapiro, MD

**Mary Crowley Medical
Research Center (Baylor)**

Dallas, TX USA
J.R. Dolan
214-658-1943
Gerald Edelman MD, PhD

XL228

*Study of XL228 Administered
Intravenously to Subjects With
Advanced Malignancies*

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: IGF1R inhibitor
Strategy: Block related tumor signal
paths
NCT #: [NCT00526838](#)
Contact: Exelixis Contact Line
1-866-939-4041

**UCLA's Jonsson
Comprehensive Cancer
Center**

Los Angeles, CA USA
Lisa Yonemoto
310-825-4477
Carolyn Britten, MD

University of Michigan
Ann Arbor, MI USA
Nabeela Iqbal
734-232-0759
David Smith, MD

Duke University
Durham, NC USA
Sharon Norman
919-681-5257
Herb Horowitz, MD

XL765

*Study of the Safety and
Pharmacokinetics of XL765 in Adults
With Solid Tumors*

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: mTOR inhibitor
PI3K inhibitor
Strategy: Block related tumor signal
paths
NCT #: [NCT00485719](#)
Contact: Exelixis Contact Line
866-939-4041

Hospital Vall d'Hebron
Barcelona, Spain
Gemma Sala +34 93 489
4158 gsala@vhebron.net
Jose Baselga, MD, PhD

Karmanos Cancer Institute
Detroit, MI USA
Theresa Laeder 313-576
-9386
Patricia LoRusso, DO

**South Texas Accelerated
Research Therapeutics
(START)**
San Antonio, TX USA
Gina Mangold, MBA 210
-413-3594
gmangold@start.stoh.com
Kyriakos Papadopoulos, MD

Treatment Stage: Palliative

Radiation

*Radiation Therapy as Palliative
Treatment of GIST (GIST-RT)*

Phase: 1
Stage: Palliative
Conditions: Gastrointestinal Stromal
Tumor
Drug Type: None
Strategy: Radiation
NCT #: [NCT00515931](#)
Contact: See site contact info below
**Helsinki University Central
Hospital**
Helsinki, Finland
947173208 Ext. 358
heikki.joensuu@hus.fi
Heikki Joensuu, MD

Sunitinib + Radiation

*Sutent and Radiation as Treatment
for Limited Extent Metastatic Cancer*

Phase: 2
Stage: Palliative
Conditions: Any type of Cancer
Drug Type: KIT/PDGFR inhibitor
Strategy: Block KIT
NCT #: [NCT00463060](#)
Contact: See site contact info below

**Mount Sinai School of
Medicine**
New York, NY USA
212-241-7503
johnny.kao@mountsinai.org
Johnny Kao, MD

Treatment Stage: Stable Disease

Imatinib

*A phase III randomized study
evaluating surgery of residual
disease in patients with metastatic
gastro-intestinal stromal tumor*

Phase: 3
Stage: Stable Disease
Conditions: Gastrointestinal Stromal
Tumor
Drug Type: KIT/PDGFR inhibitor
Strategy: Block KIT
NCT #:
Contact: Anne Kirkpatrick
Project Manager - EORTC,
Brussels, Belgium
anne.kirkpatrick@eortc.be
+32 2 7741691

**Netherlands Cancer
Institute - Antoni van
Leeuwenhoek Hospital**
Amsterdam, Netherlands